QDEL Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

35.575

Open

35.470

VWAP

33.52

Vol

1.26M

Mkt Cap

2.26B

Low

31.870

Amount

42.16M

EV/EBITDA(TTM)

8.70

Total Shares

67.93M

EV

4.82B

EV/OCF(TTM)

130.17

P/S(TTM)

0.83

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

Show More

Events Timeline

(ET)

2025-11-05

17:20:05

QuidelOrtho projects FY25 adjusted EBITDA between $585M and $605M.

2025-11-05

17:07:20

QuidelOrtho Projects $70M-$100M in COVID-19 Revenue for FY25

2025-11-05

17:06:24

QuidelOrtho aims for adjusted EBITDA margins in the mid-to-high 20% range.

2025-11-05

16:12:50

QuidelOrtho projects FY25 adjusted EPS between $2.00 and $2.15, below consensus of $2.24.

2025-11-05

16:12:18

QuidelOrtho announces Q3 adjusted earnings per share of 80 cents, surpassing consensus estimate of 47 cents.

2025-11-03 (ET)

2025-11-03

07:05:00

QuidelOrtho Secures FDA 510(k) Approval for VITROS hs Troponin I Test

News

an image of Barron's

2025-12-31Barron's

Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.

an image of Newsfilter

2025-12-18Newsfilter

QuidelOrtho Launches Podcast on Diagnostic Innovations, Enhancing Cardiac Testing Speed

an image of PRnewswire

2025-12-18PRnewswire

QuidelOrtho Releases Podcast on 2025 Diagnostic Trends, Driving Healthcare Innovations

an image of NASDAQ.COM

2025-11-24NASDAQ.COM

Insider Buying Update for Monday, November 24: QDEL, MTCH

an image of PRnewswire

2025-11-24PRnewswire

QuidelOrtho To Participate In Upcoming Investor Conferences

an image of CNBC

Midday Stock Highlights: Notable Movements from Oracle, Bath & Body Works, Gap, and Others

7 Analyst Rating

Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 34.60 USD with a low forecast of 22.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

3 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

22.00

Averages

34.60

High

62.00

Current: 0.000

Low

22.00

Averages

34.60

High

62.00

Citi

Neutral

downgrade

$33 -> $23

Al Analysis

2025-11-10

Reason

Citi

Price Target

$33 -> $23

Al Analysis

2025-11-10

downgrade

Neutral

Reason

Citi lowered the firm's price target on QuidelOrtho to $23 from $33 and keeps a Neutral rating on the shares.

JPMorgan

Underweight

downgrade

$26 -> $22

2025-11-07

Reason

JPMorgan

Price Target

$26 -> $22

2025-11-07

downgrade

Underweight

Reason

JPMorgan lowered the firm's price target on QuidelOrtho to $22 from $26 and keeps an Underweight rating on the shares. The firm views the company's Q3 report as "noisy."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QDEL

Unlock Now

Valuation Metrics

The current forward P/E ratio for QuidelOrtho Corp (QDEL.O) is 13.55, compared to its 5-year average forward P/E of 16.06. For a more detailed relative valuation and DCF analysis to assess QuidelOrtho Corp 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

5Y Average PE

16.06

Current PE

13.55

Overvalued PE

21.99

Undervalued PE

10.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

5Y Average EV/EBITDA

8.41

Current EV/EBITDA

7.38

Overvalued EV/EBITDA

10.83

Undervalued EV/EBITDA

5.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

2.15

Current PS

0.71

Overvalued PS

3.85

Undervalued PS

0.45

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is QuidelOrtho Corp (QDEL) stock price today?

The current price of QDEL is 33.2 USD — it has decreased -6.16 % in the last trading day.

What is QuidelOrtho Corp (QDEL)'s business?

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

What is the price predicton of QDEL Stock?

Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is34.60 USD with a low forecast of 22.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is QuidelOrtho Corp (QDEL)'s revenue for the last quarter?

QuidelOrtho Corp revenue for the last quarter amounts to 699.90M USD, decreased -3.74 % YoY.

What is QuidelOrtho Corp (QDEL)'s earnings per share (EPS) for the last quarter?

QuidelOrtho Corp. EPS for the last quarter amounts to -10.78 USD, increased 3493.33 % YoY.

How many employees does QuidelOrtho Corp (QDEL). have?

QuidelOrtho Corp (QDEL) has 6600 emplpoyees as of January 18 2026.

What is QuidelOrtho Corp (QDEL) market cap?

Today QDEL has the market capitalization of 2.26B USD.